{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:41Z","timestamp":1777934741322,"version":"3.51.4"},"reference-count":44,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Despite high initial response rates to chemotherapy, long-term disease control in primary central nervous system lymphoma (PCNSL) remains challenging, with high relapse rates and no universally accepted standard for induction or consolidation therapy. This review discusses current strategies, new advancements and clinical trial results for PCNSL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>An extensive Medline, Embase and Cochrane search of peer-reviewed sources reporting on pharmacotherapy of PCNSL was performed (1\/1\/2000-12\/31\/2025). Analysis of original research including clinical trial results, retrospective series and other reports were included in this review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Summary<\/jats:title>\n                    <jats:p>This review summarizes the current understanding of PCNSL, including epidemiology, clinical presentation, diagnostic evaluation, and response assessment, with a focus on pharmacologic management. We discuss modern induction strategies centered on high-dose methotrexate (HD-MTX) and rituximab, consolidation approaches including reduced-dose whole-brain radiotherapy (WBRT), autologous stem cell transplantation (ASCT), and maintenance strategies, as well as emerging therapies for relapsed or refractory disease. A case of a 76-year-old patient achieving sustained remission exceeding seven years following rituximab plus HD-MTX induction and consolidative therapy is presented to illustrate the potential for durable disease control and even cure. These data underscore the importance of individualized treatment selection based on patient age, fitness level and response to induction and highlight that lasting remission is achievable in select patients with optimized, multimodal therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Despite its rarity, PCNSL remains a therapeutically challenging malignancy. HD-MTX\u2013based chemotherapy remains the cornerstone of first-line treatment, and the addition of rituximab has been associated with more sustained responses. Although relapses are not uncommon, long-term remission is achievable. Clinical trials of newer agents, alone or added to a backbone of traditional chemotherapy, are warranted in the 1\n                      <jats:sup>st<\/jats:sup>\n                      and subsequent lines of therapy. Continued prospective research and international collaboration are essential to integrate precision oncology to the bedside of patients with PCNSL.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261430675","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:31:39Z","timestamp":1773743499000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary central nervous system lymphoma: Evolving treatment strategies to achieve improved long-term disease control"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7314-247X","authenticated-orcid":false,"given":"Moza","family":"Hamoud","sequence":"first","affiliation":[{"name":"Eisenhower Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-7546","authenticated-orcid":false,"given":"Victor M","family":"Samperio","sequence":"additional","affiliation":[{"name":"Eisenhower Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ion","family":"Codreanu","sequence":"additional","affiliation":[{"name":"Houston Methodist Research Institute"},{"name":"Department of Radiology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0425-8394","authenticated-orcid":false,"given":"Constantin A","family":"Dasanu","sequence":"additional","affiliation":[{"name":"Christus Health"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17107"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00439-0"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox187"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030403"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008377"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30050-y"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.649789"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nor014"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2000.92.2.0261"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00076-5"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142352"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3171\/foc.2006.21.5.16"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000593"},{"key":"e_1_3_2_15_2","volume-title":"NCCN clinical practice guidelines in oncology","author":"National Comprehensive Cancer Network","year":"2025","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Plymouth Meeting, PA: Central Nervous System Cancers, 2025. Version 3.2025."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.4910"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80724-0"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7667"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5062"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014073"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0164"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9957"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017014845"},{"key":"e_1_3_2_24_2","article-title":"The role of upfront lenalidomide maintenance for primary central nervous system lymphoma following first-line methotrexate treatment: a retrospective study","volume":"13","author":"Zhang Y","year":"2024","unstructured":"Zhang Y, Wang W, Zhao D, et al. The role of upfront lenalidomide maintenance for primary central nervous system lymphoma following first-line methotrexate treatment: a retrospective study. Cancer Med 2024; 13: e7193.","journal-title":"Cancer Med"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(00)00390-9"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70091-2"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14207400"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01582-5"},{"key":"e_1_3_2_29_2","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri AJM","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 2016 May; 3: e217\u2013e227.","journal-title":"Lancet Haematol"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.524"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30747-2"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000001401"},{"key":"e_1_3_2_33_2","article-title":"High dose methotrexate (MTX) treatment: Value of post treatment MTX level monitoring and risk factors for acute kidney injury","volume":"41","author":"Synyder R","year":"2023","unstructured":"Synyder R. High dose methotrexate (MTX) treatment: Value of post treatment MTX level monitoring and risk factors for acute kidney injury. J Clin Oncol 2023; 41: e19539.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70105-4"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2023.2193325"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now033"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.03.008"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.170"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0605"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104597"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa145"},{"key":"e_1_3_2_42_2","article-title":"Meta-analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary central nervous system lymphoma","volume":"131","author":"Tan S","unstructured":"Tan S, He H, Ni J, et al. Meta-analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary central nervous system lymphoma. Cancer 2025 Sept 15; 131: e70083.","journal-title":"Cancer"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz032"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-835496"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014635"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261430675","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261430675","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261430675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:32:32Z","timestamp":1777689152000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261430675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":44,"alternative-id":["10.1177\/10781552261430675"],"URL":"https:\/\/doi.org\/10.1177\/10781552261430675","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"article-number":"10781552261430675"}}